Pharma Capital

Pre-clinical data on liver disease candidate sends Ocera Therapeutics shares higher

The data will be given in what's called a poster presentation in the Netherlands.
liver.jpg
The candidate showed encouraging results on non-alcoholic fatty liver disease

Shares in Ocera Therapeutics Inc (NASDAQ:OCRX) raced up almost 20% as it reported positive pre-clinical data on its candidate OCR-002 ability to deal with non-alcoholic fatty liver disease (NAFLD) .

Shares in the biotech company gained 19.33% to $1.42 each.

The data will be given in what's called a poster presentation in the Netherlands.

The study investigated the effect of OCR-002 in a rat with the disease in which animals were fed a High Fat and High Cholesterol (HFHC) diet for up to 16 weeks.

NAFLD rats treated with OCR-002 showed significant reduction in the progression of fibrosis compared to untreated NAFLD animals and OCR-002 substantially reduced the liver/body weight ratio, the hepatic lipid content, and hepatic collagen.

“We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement,” said Stan Bukofzer, Ocera’s chief medical officer.

Giles_55af4ddca6481.jpg


Register here to be notified of future Company articles
View full profile

Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.